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SUMMARY 
 
The nuclear receptor (NR) superfamily is a large class of pharmacologically important 
receptors that play vital roles in the defence mechanisms in the human body. It is 
responsible for protecting the body from a diverse array of harmful endogenous and 
exogenous toxins by modulating the expression of the genes involved in drug metabolism 
and disposition. The detoxifying and elimination of these toxins is mainly mediated by 
cytochrome P450 (CYP) enzymes, along with phase I and phase II drug metabolising 
enzymes, as well as drug transporters.  
 
Three closely related nuclear receptors, namely the pregnane X receptor (PXR), 
constitutive androstane receptor (CAR) and hepatocyte nuclear factor 4-alpha (HNF4α) 
have recently been identified as the master transcriptional regulators of CYPs expression. 
The human CYP3A sub-family collectively comprises the largest portion of CYP 
proteins expressed in the liver and they are involved in the metabolism of more than 60% 
of all currently prescribed drugs. CYP3A4, the most abundantly expressed CYP3A 
isoform, is considered as the main oxidase for these drugs in the liver. In recent years, 
much work had been carried out to identify single nucleotide polymorphisms (SNPs) in 
the three receptor genes (PXR, CAR and HNF4α) and to examine the significance of 
these SNPs in relation to CYPs expression in terms of drug disposition or responsiveness. 
It is hypothesized that genetic variation in these nuclear receptors may contribute to 
human inter-individual variation in drug metabolism and also drug-drug interactions.  
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The first part of this study aims to identify SNPs in the exons of the PXR, CAR and 
HNF4α genes in the local healthy population. We identified a 5’ UTR variant for the 
PXR gene (- 24381 A > C), one variant for the CAR gene (Pro180Pro) and two coding 
variants for the HNF4α gene (Met49Val and Thr130Ile). The second part of this study 
was conducted to screen for SNPs in breast cancer patients administered with docetaxel 
in their chemotherapy treatment. The objective of the second study was to address the 
clinical significance of the SNPs identified in the receptor genes in relation to docetaxel 
kinetics.  Docetaxel is an anti-cancer agent that is metabolised by CYP3A4. Thus, any 
SNPs in these receptor genes could possibly affect docetaxel clearance in the breast 
cancer patients. From our data, the same four variants were again identified in the breast 
cancer cohort. No additional SNP was observed. Statistically, no significant correlation 
was noted for the docetaxel clearance, body-surface-area normalised docetaxel clearance, 
area under curve and half-life for PXR, CAR and HNF4α genes. In conclusion, the SNPs 
identified in the PXR, CAR and HNF4α genes in this study appear not to have any 
significant contribution to the variability in docetaxel clearance among the breast cancer 
patients. 
     vi
LIST OF TABLES 
 
 
Table 1 Summary of the major drug metabolising cytochrome P450 enzymes,  
their main tissue localisation and the anti-cancer agents which  
they metabolise……………………………………………………………. 6 
 
Table 2   Summary of the tissue distribution and type of reactions catalyzed by  
some human cytochrome P450 enzymes involved in the maintenance  
of cellular homeostasis……………………………………………………. 7 
 
Table 3  List of reagents needed for this study and the suppliers………………….. 35 
 
Table 4  A set of PCR forward and reverse primers that were used to amplify  
each individual exonic region of the PXR  gene…………………………. 40 
 
Table 5  A set of PCR forward and reverse primers that were used to amplify  
each individual exonic region of the CAR gene……………………….… 41 
 
Table 6  A set of PCR forward and reverse primers that were used to amplify  
each individual exonic region of the HNF4α gene……………………… 42 
 
Table 7  Forward and reverse primers for pyrosequencing………………………. 45 
 
Table 8 Polymorphisms identified in the PXR, CAR and HNF4α gene in the 
healthy control population (n = 287)…………………………………… 56 
 
Table 9  Genotypic distribution and allele frequencies of PXR, CAR  
and HNF4α variants in healthy control………………………………... 57 
 
Table 10  Comparison of SNP frequencies of PXR exon 1 variant……………… 58 
 
     vii
Table 11 Comparison of SNP frequencies of CAR exon 5 variant……………… 58 
 
Table 12  Comparison of SNP frequencies of HNF4α exon 1C variant…………. 59 
 
Table 13  Comparison of SNP frequencies of HNF4α exon 4 variant……………59 
 
Table 14  Genotypic distribution and allele frequencies of PXR, CAR  
and HNF4α variants in breast cancer patients (n = 101)……………….61 
 
Table 15  Genotypic distribution and allele frequencies of PXR, CAR  
and HNF4α  for the different ethnic groups in the breast cancer  
population (n = 101)………………………………………………….. 62 
     viii
LIST OF FIGURES 
 
Figure 1 Pie chart illustrations of phase I and phase II drug metabolising  
enzymes……………………………………………………………….. 3 
 
Figure 2 The schematic organization of the human CYP3A locus………………9 
 
Figure 3 Transcription factor binding sites within the regulatory regions  
of human CYP3A4 gene……………………………………………….11 
 
Figure 4 Structure of a typical nuclear receptor……………………………….. 15 
 
Figure 5 The structure of HNF4α gene and its spliced isoforms……………… 22 
 
Figure 6 An illustration of the effects of docetaxel in tumour cell……………. 27 
 
Figure 7 Proposed metabolic pathways of docetaxel by CYP3A enzymes…... 30 
 
Figure 8  A summary of the functions of PXR, CAR and HNF4α in drug  
                  detoxification and elimination………………………………………. 33 
 
Figure 9   Flow chart showing the study approach to identify PXR, CAR  
and HNF4α SNPs in healthy subjects and breast cancer patients…..  34 
 
Figure 10 The principle of Pyrosequencing……………………………………..44 
 
Figure 11  PCR amplification of all nine PXR exons from patient genomic  
DNA……………………………………………………………….... 50 
 
Figure 12  PCR amplification of all eight CAR exons from patient genomic  
DNA………………………………………………………………… 50 
     ix
 
 
Figure 13  PCR amplification of all twelve HNF4α exons from patient  
genomic DNA…………………………………………….……….... 51 
 
Figure 14 PCR amplification of PXR exon 1, CAR exon 5, HNF4α  
exon 1C and HNF4α exon 4 from patient genomic DNA using 
Pyrosequencing primers……….…………………………….……...  51 
 
Figure 15 Electropherograms of PXR, CAR and HNF4α SNPs……….….…..  52 
 
Figure 16  Docetaxel clearance (L/h/m2) against PXR exon 1, CAR  
exon 5, HNF4α exon 1C and HNF4α exon 4 genotypes...………...  66 
 
Figure 17 BSA normalised docetaxel clearance (L/h/m2) against PXR  
exon 1, CAR exon 5, HNF4α exon 1C and HNF4α exon 4  
genotypes…………………………………………………………...  68 
 
Figure 18 Maximum concentration of docetaxel, Cmax, (mg/L) against  
PXR exon 1, CAR exon 5, HNF4α exon 1C and HNF4α exon 4  
genotypes……………………………………………………………70 
 
Figure 19 Area under curve, AUC, (mg/L*h) against PXR exon 1, CAR  
exon 5, HNF4α exon 1C and HNF4α exon 4 genotypes………..… 72 
 
Figure 20 Half life, t1/2, (hours) against PXR exon 1, CAR exon 5, HNF4α  
exon 1C and HNF4α exon 4 genotypes…………………………… 74 
 
     x
LIST OF ABBREVIATIONS 
 
 
ADH   Alcohol dehydrogenase 
AF-1   Activation function 1 
AF-2   Activation function 2 
ALDH    Aldehyde dehydrogenase 
APS   Adenosine 5’ phosphosulfate 
AUC   Area under the concentration-time curve 
Bp   Base pair 
CAR   Constitutive androstane receptor 
CCD   Charged coupled device 
CL   Clearance 
CLEM   Constitutive liver enhancer module 
Cmax   Maximum concentration 
COMT    Catechol O-methyl-transferase 
CRE   cAMP response element 
CYP    Cytochrome P450  
CYPOR  cytochrome P450 oxidoreduactase 
DBD   DNA binding domain 
DME   Drug metabolizing enzyme 
dNTP   Deoxyribonucleotide triphosphate 
DPD    Dihydropyrimidine dehydrogenase  
DR   Direct repeat 
ER    Everted repeat 
EST   Expressed-Sequence Tag 
GRE   Glucocorticoid responsive element 
GST    Glutathione S-transferase 
HMT    Histamine methyl-transferase  
HNF4α  Hepatocyte nuclear factor 4- alpha 
HSP   Heat shock protein 
Ile   Isoleucine 
     xi
IR   Inverted repeat 
k   Elimination rate constant 
LBD   Ligand binding domain 
Met   Methionine 
MDR   Multidrug resistance 
MODY  Maturity-onset diabetes in the young 
MRP   Multidrug resistance associated protein 
NADPH  Nicotinamide adenine dinucleotide 
NAT    N-acetyl-transferase  
NHR   Nuclear hormone receptor 
NQO1    NADH:quinone oxidoreductase or DT diaphorase  
NR   Nuclear receptor 
NUMI   National University Medical Institute 
OATP   Organic anion transporter 
PAR   Pregnane activated receptor 
PCN   Pregnenolone 16α-carbonitrile 
PCR   Polymerase chain reaction 
P-gp   P-glycoprotein 
PPi   pyrophosphate 
Pro   Proline 
PXR   Pregnane X-receptor 
RE   Response element 
RORα   Retinoic acid receptor alpha 
RXR   Retinoid X receptor 
SAP   Shrimp Alkaline Phosphatase 
SNP   Single nucleotide polymorphism 
ST    Sulfotransferase  
SULT   Sulfotransferase  
SXR   Steroid and xenobiotic receptor 
t1/2   Half life 
TAE   Tris-Acetate-EDTA 
     xii
Thr   Threonine 
TPMT    Thiopurine methyl-transferase  
UGT    Uridine 5’-triphosphate glucuronosyltransferases. 
USF-1   Upstream stimulatory factor 1 
UTR   Untranslated region 
Val   Valine 
XREM   Xenobiotic-responsive enhancer module 
     1
1. INTRODUCTION 
 
1.1 Drug Metabolism and Disposition 
 
The body’s first line of defence against the accumulation of potential toxic 
endogenous and exogenous lipophilic compounds is the liver. This is the site 
where drugs and toxic xenobiotics are being transformed to less toxic water 
soluble metabolites that subsequently can be excreted out of the body. In multi-
cellular organisms, two different defence mechanisms have evolved for this 
purpose, biotransformation and transport. Biotransformation and transport 
processes comprise three phases; phase I (functional reaction) and phase II 
(conjugative reaction) form the biotransformation or drug metabolism pathway 
while phase III forms the drug transportation and disposition pathway (Gibson 
and Skett, 2001). 
  
The phase I enzymes are responsible for primary modification of lipophilic 
compounds into more polar forms. Phase I reactions generally include oxidation, 
reduction, hydrolysis, hydration, dethioacetylation and isomerisation. On the other 
hand, Phase II reactions include glucuronidation, glycosidation, methylation, N-
acetylation, sulfation, amino acid and glutathione conjugation. (Gibson and Skett, 
2001; Handschin and Meyer, 2003) Phase II comes into play by acting on phase I 
metabolites or on the parent compounds to further convert or detoxify to inactive 
derivatives, which accounts for bulk of the excreted products. Thus, phase II 
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reactions are considered the true “detoxification” pathway. However, there are 
instances where phase II reactions lead to reactive metabolites. Phase III 
comprises the transport and elimination steps where the parent drug and its 
metabolites are exported out of the cell and eventually removed from the body 
through the bile or urine. Figure 1 illustrates the contribution of phase I and phase 
II enzymes to the metabolism of drugs. 
     3
 
 
Figure 1: Pie chart illustrations of phase I and phase II drug metabolising 
enzymes. The relative size of each section on the charts show the relative 
contribution of each phase I and phase II enzymes to drug metabolism. Phase I 
enzymes are responsible for modification of functional groups and phase II is 
involved in conjugation with endogenous substituents. ADH, alcohol 
dehydrogenase; ALDH, aldehyde dehydrogenase; CYP, cytochrome P450; DPD, 
dihydropyrimidine dehydrogenase; NQO1, NADH:quinone oxidoreductase or 
DT diaphorase; COMT, catechol O-methyl-transferase; GST, glutathione S-
transferase; HMT, histamine methyl-transferase; NAT, N-acetyl-transferase; 
STs, sulfotransferase; TPMT, thiopurine methyl-transferase; UGTs, uridine 5’-
triphosphate glucuronosyltransferases. Adapted from Evans and Relling, 1999, 
with permission from The American Association for the Advancement of 
Science. 
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1.2 Cytochrome P450 
 
Cytochrome P450 (CYPs) enzymes were first discovered in 1958 by Martin 
Klingenberg while studying the spectrophotometric properties of rat liver 
microsomal pigments. The name P450 was derived from the property of these 
pigments which has a maximum absorbance reading at 450nm (Hasler et al., 
1999). CYPs constitute a superfamily of heme-thiolate containing proteins that 
belong to a group of enzymes involved in hepatic detoxification of endogenous 
and exogenous compounds (phase I enzymes). CYP, together with its reducing 
counterpart nicotinamide adenine dinucleotide (NADPH) - cytochrome P450 
oxidoreductase (CYPOR), is able to catalyze mono-oxygenase reactions with 
lipophilic compounds by allowing the attachment of a hydroxyl group as a 
reactive group that can later be modified by phase II enzymes (Handschin and 
Meyer, 2003). 
 
CYPs play an important role in the maintenance of the human cellular 
homeostasis. Predominately express in the human liver, CYPs metabolize a wide 
spectrum of endogenous steroid hormones, bile acids, fatty acids and xenobiotic 
substrates such as drugs, carcinogens, food additives, pollutants and 
environmental chemicals. 
 
In human beings, there are 18 known CYP gene families and 43 subfamilies 
(Kretschmer and Baldwin, 2005; Nelson DR, 2003). Only three of these, CYP1, 
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CYP2 and CYP3, are actively involved in drugs and xenobiotics metabolism. 
Members of CYP1A, CYP2B, CYP2C and CYP3A gene subfamilies are highly 
inducible by a diverse array of xenobiotics (Handschin and Meyer; 2003). Besides 
being involved in drug metabolism, these CYPs also play an important role in 
cholesterol biosynthesis, vitamin D metabolism, bile acid metabolism, 
biosynthesis and catabolism of steroids (Pascussi et al., 2003; Nelson DR, 1999). 
In the CYP family, the major isoforms responsible for drug metabolism are 
CYP2C9, CYP2C19, CYP2D6 and CYP3A4 (Ingelman-Sundberg, 2004). Table 1 
shows the main tissue localisation of these CYPs and their anti-cancer substrates 
(Ingelman-Sundberg, 2004; Van Schaik, 2005). 
 
Different forms of CYP are found to be expressed in intestine, lung and kidneys 
but the liver is the major site for CYP-mediated oxidative metabolism, with 
CYP3A family as the dominant class. In this study, the focus will be on the 
CYP3A sub-family members. This is because of their dominant role in drug 
metabolism in the liver, and their regulation by nuclear receptors. Table 2 shows 
the reactions catalysed by CYPs in humans and their tissue localization.  
 
















Cyclophosphamide          Tamoxifen 






Thalidomide                     Ifosfamide 















Cyclophosphamide          Imatinib / Gleevec 
Ifosfamide                        Irinotecan 
Docetaxel                         Paclitaxel / Taxol 
Etoposide                         Teniposide 
Flutamide                         Tamoxifen 




Table 1: Summary of the major drug metabolising cytochrome P450 enzymes, 
their main tissue localisation and the anti-cancer agents which they metabolise. 
Adapted from Ingelman-Sundberg, 2004; Van Schaik, 2005.








Liver and Intestine 
 
(i)     Bile acid formation 
(ii)    Polyunsaturated fatty acid epoxidation  
(iii)   Xenobiotic metabolism 
              ► N- & O-dealkylations 
              ► Alcohol oxidation 
              ► Alkane & Arene oxygenation 
















(i)     Aromatase 
 
Table 2: Summary of the tissue distribution and type of reactions catalyzed by 
some human cytochrome P450 enzymes involved in the maintenance of cellular 
homeostasis. Reactions include (a) synthesis and degradation of prostaglandins 
and other unsaturated fatty acids, (b) metabolism of cholesterol to bile acids and 
(c) metabolism of endogenous and exogenous compounds (Hasler et al., 1999) 
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1.2.1 CYP3A 
 
The human CYP3A sub-family is relatively small, comprising only four members; 
CYP3A4, CYP3A5, CYP3A7 and CYP3A43 which are mapped on human 
chromosomal position 7q21-q22.1 (Figure 2) (Gellner et al., 2001; Plant, 2007). 
CYP3As can be induced by a large array of compounds. These include naturally 
occurring and synthetic glucocorticoids, pregnane compounds such as 
pregnenolone 16α-carbonitrile (PCN) and macrolide antibiotics like rifampicin 
(Quattrochi and Guzelian, 2001). Inter-individual variability in induction of 
CYP3A activity by these compounds could be due to the genetic variation of 
CYP3A sub-family members or its transcription regulators. To date, the number of 
variants for CYP3A4, 3A5, 3A7 and 3A43 are 40, 24, 7 and 5 respectively. This 
information is published on the official allele nomenclature committee website 
(http:www.imm.ki.se/CYPalleles) (Plant, 2007).  
 
As the most abundantly expressed CYP3A isoform in the human liver and 
intestine, CYP3A4 is one of the best studied member of the CYP3A gene sub-
family. CYP3A4 plays a crucial role in the metabolic elimination of a broad range 
of structurally diverse substrates and thus contributes critically to the first-pass 
and systemic metabolism in the human body.  
 
 









Figure 2: The schematic organization of the human CYP3A locus. The assembled 231kb 
sequence contains the four CYP3A sub-family members, CYP3A4, CYP3A5, CYP3A7 and 
CYP3A43. This cluster is localised on chromosome 7q21-7q22.1 (Burk and Wojnowski, 
2004; Finta and Zaphiropoulos, 2000). Both CYP3A4 and CYP3A5 genes contain 502 
amino acids each and they have molecular weights of 57299 Dalton and 57109 Dalton 
respectively.  CYP3A7 and CYP3A43 genes each contain 503 amino acids with molecular 




CYP3A43 CYP3A4 CYP3A7 CYP3A5 
     10
1.2.2 CYP3A4 
 
CYP3A4 is most abundantly expressed in the liver and small intestine. Accounting 
for 30-40% of the total CYPs in the liver, CYP3A4 is considered as the main 
oxidase for xenobiotics in this organ. It is catalytically effective on cyclosporine, 
macrolide antibiotics, anti-cancer agents such as taxol and is responsible for the 
metabolism of more than 60% of the prescribed drugs marketed today (Hasler et 
al., 1999; Kretschmer and Baldwin, 2005; Plant, 2007). CYP3A4 is also expressed 
weakly in stomach, colon, lung and adrenal (Guengerich, 2005). 
 
Other than its own genetic variations that could possibly contribute to inter-
variation in drug metabolism, genetic variation in its regulatory transcriptional 
partners could also affect how efficiently the gene is transcribed and expressed. 
This would eventually have an impact on drug clearance processes, which is an 
important determinant of drugs efficacy and toxicity. In recent studies, pregnane 
X-receptor (PXR), constitutive androstane receptor (CAR) and hepatocyte nuclear 
factor 4- alpha (HNF4α) have been identified to serve key roles in regulating 
CYP3A4 transcription (Quattrochi and Guzelian, 2001; Burk and Wojnowski, 
2004). This seems reasonable as PXR, CAR and HNF4α binding sites have been 
revealed in the CYP3A4 gene (Figure 3) and would be further discussed in Section 
1.4 Thus, any variability in these transcriptional controls could also either up-
regulate or down-regulate CYP3A4 activity. 


















Figure 3: Transcription factor binding sites within the regulatory regions of human 
CYP3A4 gene. The two regulatory regions shown are CLEM4 and XREM that lies 
upstream of CYP3A4 promoter (Plant, 2007). HNF4α binding sites have been identified 
in both CLEM4 and XREM regions of CYP3A4 gene. PXR and CAR bind to the same 
















P/GRE HNF 4 RORα CAAT PXRE PXRE P/GRE
-7840 -7270 
CLEM4 Region 
 XREM Region 
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1.2.3  CYP3A5 
  
 CYP3A5 or H1p3 has approximately 85% sequence identity to CYP3A4. CYP3A5 
is found to be expressed in liver, small intestine, kidney, lung, prostate and 
adrenal gland. CYP3A5 accounts for approximately 20% of total hepatic CYPs. 
Unlike CYP3A4, CYP3A5 is polymorphically expressed in fetal liver. The 
regulation and catalytic selectivity of CYP3A5 has also been documented.  
Comparison of the metabolic capabilities of the CYP3A isoforms for a series of 
CYP3A substrates (including midazolam, alprazolam, triazolam, clarithromycin, 
tamoxifen, testosterone, estradiol, diltiazem, nidefipine and 7-benzyloxy-4-
trifluoromethylcoumarin) showed that CYP3A5 generally has lower affinities for 
these substrates than CYP3A4 (Williams et al., 2002). In addition, the clearance 






 CYP3A7 was initially named as HFLa. It is the main CYP present in human fetal 
liver, when CYP3A4 is not expressed. CYP3A7 was believed to be significantly 
down regulated after birth, even though low levels of approximately less than 2% 
of the total CYPs in adult liver has been detected in some individuals (De Wildt et 
al., 1999; Guengerich, 2005). Other known expression sites include kidney, lung 
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and adrenal. Compared to other CYP3A members, less work has been done on 
CYP3A7 in relation to drug metabolism. However, it has been shown that 
CYP3A7 has a significantly weaker metabolic capacity (in terms of affinity and 





 CYP3A43 was first characterized in 2001 by three groups and is found to be 
expressed in liver, kidney, pancreas and prostate (Domanski et al., 2001; Gellner 
et al., 2001; Westlind et al., 2001). The level of expression of CYP3A43 was 
considerably low in human liver, accounting for only approximately 0.1% of 
CYP3A isoforms (Guengerich, 2005). Since, the main site of drug metabolism in 
the human system is the liver, CYP3A43 is deemed to make little contribution to 
this aspect due to its low expression.  
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1.3 Nuclear Receptors 
 
Nuclear hormone receptors (NHRs) constitute a superfamily of ligand-dependent 
and ligand-independent transcription factors that govern important physiological 
processes such as development, homeostasis and disease. To date, more than 50 
nuclear receptors have been identified in various species. They generally have two 
transcription activation function domains (AF-1 and AF-2) located at the amino 
and carboxyl termini respectively, a zinc finger DNA binding domain and a 
ligand binding domain as illustrated in Figure 4. NHRs are able to induce or 
regulate drug metabolism by binding to small lipophilic ligands. Following ligand 
binding and dimerization, they then bind to DNA element repeats of the 
nucleotide hexamers in different arrangements like the ones found in drug-
responsive enhancers of CYPs. The hexamers can be arranged either as direct 
repeats (DR), everted repeats (ER) or inverted repeats (IR).  Upon binding to a 
specific ligand, the receptor may undergo a conformational change that either 
facilitates the binding of co-activator proteins or interaction to fellow transcription 
factors which eventually regulates the transcriptional activity of the target gene.   
 







Figure 4: Structure of a typical nuclear receptor. Nuclear receptors share a 
common modular structure which consists of activation function 1 (AF-1) domain 
located at the amino-terminal and AF-2 domain at the carboxy-terminal. The 
DNA binding domain (DBD) is connected to the ligand binding domain (LBD) by 
a flexible hinge. Upon ligand binding to the LBD, AF-2 will undergo a 
conformational change that disrupts interaction with transcriptional co-repressors 
and allows the interaction with transcriptional co-activators. The activated nuclear 
receptor will then bind to the response elements on the regulatory regions of 
target genes and initiates transcription.  
 
 
AF-1 DBD Hinge LBD AF-2  N 
 
C 
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NHRs are categorized into three main classes.  Class I receptors bind to steroid 
hormones and in absence of ligand, these receptors are associated with molecular 
chaperones like heat shock proteins (HSPs). Class II receptors bind to thyroid 
hormone, vitamin D3, 9-cis-retinoic acid and trans-retinoic acid. Upon binding of 
ligands, class II receptors dimerizes with retinoid X receptor (RXR). In both 
cases, upon binding ligand binding, the receptors may undergo conformational 
changes that eventually cause the dissociation of co-repressors and binding of co-
activators. Class III belongs to a group of receptors whose physiological ligands 
have not yet been identified (Handschin and Meyer, 2003; Pascussi et al., 2003)  
 
Over the past decades, some members of the NHR superfamily were termed 
‘orphan’ receptors because at the time of their cloning, nothing was known about 
their physiological ligands or co-activators. Till now, the term remains for these 
receptors even though their ligands are now known. The first ‘orphan’ receptor 
was identified in 1988 and since then, the number of orphan receptors has 
increased tremendously (Wang and LeCluyse, 2003; Kliewer, 2005). Scientists 
are not only interested in researching on the novel physiological ligands of these 
orphan receptors but also the biological functions and signaling cascades that 
these receptors elicit. The next part of the introduction will focus on three 
members of the NHR superfamily (PXR, CAR and HNF4α) and their relationship 
with the CYP family.  
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1.3.1 Pregnane X Receptor 
 
The pregnane X receptor (PXR, NR1I2), also known as pregnane activated 
receptor (PAR) or the steroid and xenobiotic receptor (SXR), is a member of the 
NHR superfamily. The PXR gene is located on chromosome 3q12-q13.3 and 
consists of nine exons. The size of this gene is approximately 38kb. The length of 
the unprocessed precursor protein is 434 amino acid long and it has a molecular 
weight of 49762 Dalton (http://www.expasy.org/uniprot/O75469). PXR was first 
discovered in 1997 from a search performed on the Washington University Mouse 
Expressed-Sequence Tag (EST) database (Kliewer et al., 1998). It derived its 
name based on its activation by 21-carbon steroids (pregnanes), namely 
pregnenolone 16α-carbonitrile (PCN) (Willson and Kliewer, 2002; Kliewer, 
2005)  
 
PXR coordinates the induction and regulation of phase I and II DMEs, and phase 
III drug transporters that accelerate systemic clearance upon drug exposure. Phase 
I enzymes that are regulated by PXR include CYP3As, CYP2Bs and CYP2Cs 
(Bertilsson et al., 1998; Blumberg et al., 1998; Kliewer et al.,1998; Lehmann et 
al., 1998). Phase II enzymes include uridine diphospho-glucuronosyltransferases 
1A1 (UGT1A1), glutathione-S-transferase 1 (GST1) and sulfotransferase 2A1 
(SULT 2A1), and phase III enzymes include drug efflux transporters such as 
multidrug resistance 1 (MDR1), multidrug resistance associated proteins 2, 3 and 
4 (MRP2, MRP3 and MRP4) as well as uptake transporter like Na+-independent 
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organic anion transporter 2 (Oatp2) (Kretschmer and Baldwin, 2005; Lamba et 
al., 2005). 
 
PXR resides in the cytoplasm. Upon activation by ligand binding, PXR 
heterodimerised with RXR and subsequently binds to PXR response elements in 
the promoter region of target genes, such as the CYP3A genes. PXR, like its 
primary target CYP3A4, is expressed predominantly in the liver and to a lesser 
extent in the colon and small intestine (Blumberg et al., 1998; Kliewer et al., 
1998; Lehmann et al., 1998; Lamba et al., 2005)      
 
 
1.3.2 Constitutive Androstane Receptor  
 
The constitutive androstane receptor (CAR, NR1I3) was initially known as 
MB67. CAR regulates the drug metabolism and disposition pathway and the gene 
encoding for CAR is located on chromosome 1q23.3 and consists of 9 exons. The 
size of this gene is approximately 8.5kb. The length of the unprocessed precursor 
protein is 352 amino acid long and it has a molecular weight of 39942 Dalton 
(http://www.expasy.org/uniprot/Q14994). CAR was first identified in 1994 
through screening of a cDNA library using a nuclear receptor DNA binding 
domain (DBD)-based oligonucleotide probe. It was originally known as 
constitutive activated receptor as it could transactivate target gene as a 
     19
heterodimerised complex with RXR in the absence of ligands (Wang and 
LeCluyse, 2003; Lamba et al., 2005) 
 
CAR, like PXR, is predominately expressed in liver and intestine, and regulates a 
variety of drug detoxifying genes (Pascussi et al., 2003). These include the 
CYP3As, CYP2Bs, CYP2Cs, UGT1A1, GST, SULT, MDR1, MRP2, MRP3 and 
MRP4 (Handschin and Meyer, 2003; Lamba et al., 2005). CAR resides in the 
cytoplasm and translocates into the nucleus upon binding to its ligand (Kawamoto 
et al., 1999; Savkur et al., 2003; Tirona and Kim, 2005). Interestingly, there are 
evidences that suggest ligand binding is not always necessary for CAR 
translocation (Goodwin and Moore, 2004). Thus, it appears that there might be 
some unidentified cellular signaling cascade regulations, crosstalk or feedback 
mechanisms that could trigger the translocation and activation of CAR.    
 
 
1.3.3 Hepatocyte Nuclear Receptor 4-alpha 
 
Hepatocyte nuclear receptor 4-alpha (HNF4α, NR2A1) is a member of the NHR 
that was first identified in 1989 in crude rat liver nuclear extracts (Costa et al., 
1989; Sladek et al., 1990). It plays important roles in metabolic processes in the 
liver and is involved in glucose homeostasis and insulin secretion in the pancreas. 
HNF4α also plays a critical role in development and cell differentiation (Odom et 
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al., 2004). HNF4α is highly expressed in liver, kidney and intestine and to a 
lesser extent in pancreas and stomach (Sladek and Seidel, 2001) 
 
This gene is localized on chromosome 20q12-q13.1 and consists of 10 exons. The 
size of this gene is approximately 75.6kb. The length of the unprocessed precursor 
protein is 474 amino acid long and it has a molecular weight of 52785 Dalton 
(http://www.expasy.org/uniprot/p41235). At least nine possible HNF4α isoforms 
can be generated through alternative promoters (P1 and P2) usage and splicing 
(Figure 5), although to date, only four have been detected in vivo. The P2 
promoter lies at approximate 45.5kb upstream of P1 promoter. The different 
isoforms expression varies with development stages, differentiation and tissue 
origin. In adult liver and kidney, the expression of HNF4α is initiated mainly at 
the P1 promoter (Nakhei et al., 1998; Sladek and Seidel, 2001). It was also 
demonstrated that the HNF4α P1 promoter transcription site exhibits stronger 
transcriptional activity and recruits co-activators more efficiently as compared to 
the P2 promoter. This could be explained by the presence of the activation 
function domain AF-1 which is encoded by exon 1A proximal to P1 promoter 
initiation site. AF-1 plays a crucial role in HNF4α transcriptional potential and 
interaction with its co-activators (Green et al., 1998; Kistanova et al., 2001; 
Eeckhoute et al., 2001; Eeckhoute et al., 2003).  
 
HNF4α was originally known as an ‘orphan’ nuclear receptor as its physiological 
ligands were not identified. However, fatty acyl-CoA thioesters were recently 
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shown to be the natural putative ligand of HNF4α (Dhe-Paganon et al., 2002). 
Like PXR and CAR, HNF4α also plays a significant role in the regulation of 
CYPs. But unlike them, HNF4α is not associated with RXR and functions as 
homodimers that subsequently bind to specific DNA response elements. 
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Figure 5: The structure of HNF4α gene and its spliced isoforms. Adapted from Sladek and 
Seidel, 2001, with permission from Elsevier 
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1.4 Regulation of CYP3A Expression by PXR, CAR and HNF4α  
 
PXR and CAR are considered to be the master regulators of drug clearance in the 
body because of their close relationship with the key DMEs, CYP3A4 and 
CYP2B6. This was further supported by studies which show that PXR-RXRα and 
CAR-RXRα heterodimers are capable of binding to the proximal promoter region 
of the CYP3A4 gene and mediates PXR or CAR transactivation of the CYP3A4 
promoter respectively (Bertilsson et al., 1998; Goodwin et al., 2002; Akiyama 
and Gonzalez, 2003). The activation of CYP3A4 promoter by the nuclear 
receptors heterodimer is dependent upon ligand binding leading to the binding of 
the nuclear receptors to the response elements (REs) in the 5’ flanking region of 
CYP3A4. Transactivation of CYP3A4 by PXR and CAR upon ligand activation is 
mediated by the “proximal ER6” element located at -153bp to -170bp, and by the 
DR3 motif at the distal xenobiotic-responsive enhancer module (XREM) 
(Goodwin et al., 2002) (Figure 3). It has also been shown that regulation by PXR 
and CAR extended well beyond the CYP3A4 gene. Together, PXR and CAR co-
regulate members of CYP2B, CYP2C, GST, SULT, MRP2 and UGT families 
(Kliewer et al., 2002). 
 
In 2004, a second enhancer module that confers constitutive activation of the 
CYP3A4 gene was identified by Matsumura’s group. It is known as the 
constitutive liver enhancer module (CLEM4) and is located between -11400bp 
and -10900bp upstream of CYP3A4 promoter (Figure 3). Because of the poor 
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sequence conservation of CLEM4 between the CYP3A gene members, CLEM4 
appears to be specific for regulation of CYP3A4 expression (Matsumura et al., 
2004; Plant, 2007).  
 
Beside PXR and CAR, HNF4α also emerges as one of the widely acting 
transcription factor in the liver. Not only does HNF4α regulates DMEs such as 
CYP3A4, CYP3A5, CYP2A6, CYP2B6, CYP2C9 and CYP2D6, it is also 
involved in transcriptional regulation of glucose, cholesterol, fatty acid, urea and 
bile acid metabolism (Akiyama and Gonzalez, 2003). In addition, mutations in 
human HNF4α gene is linked to maturity-onset diabetes in the young (MODY1) 
and is characterized by defective secretion of insulin by the pancreatic-β cells 
(Ryffel, 2001; Gupta et al., 2005). Most importantly, an HNF4α binding site was 
identified in both the PXR and CYP3A4 promoter region (Kamiya et al., 2003; 
Burk and Wojnowski, 2004). In addition, two other binding sites have been 
identified in the CYP3A4 gene, one within the CLEM4 region and the other within 
the XREM region (see Figure 3). The HNF4 binding site identified within the 
CLEM4 has been assessed and was found to be necessary for maximal enhancer 
activity (Plant, 2007). The HNF4α binding site (DR1) identified in the CYP3A4 
XREM region lies between -7783bp and -7771bp, adjacent to the DR3 motif. In 
the studies done by Tirona et al (2003), it was demonstrated that the binding of 
HNF4α to DR1 can confers maximal PXR-mediated transcriptional activation. 
Similar to that observed for PXR, HNF4α was also able to augment the activation 
of the CYP3A4 promoter by CAR.  
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Other sources of evidence that support the importance of PXR, CAR and HNF4α 
as the regulators of CYP3A induction came from work in animal models. PXR and 
CAR null mice failed to induce CYP3A activity upon induction by respective 
agonists. HNF4α deficient fetal mice, too, demonstrated absence of CYP3A and 
PXR mRNAs. Reduced level CYP3A mRNA was also observed in adult mice 
with deleted hepatic Hnf4a gene (Honkakoski et al., 2003). Thus, it is now 
evident that HNF4α not only influences the basal activity of the CYP3A promoter, 
it is also necessary for maximal PXR- or CAR- mediated transcriptional activation. 
 
Hence, any sequence variations in the three nuclear receptors, PXR, CAR and 
HNF4α would likely contribute to altered induction of target DME genes such as 
CYP3A and this would eventually affects the systemic clearance of xenobiotics, 
homeostasis, development and disease.  
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1.5 Docetaxel 
 
Docetaxel [4 - acetoxy - 2α - benzoyloxy - 5β, 20 – epoxy - 1, 7β - 10β -
trihydroxy – 9 – oxotax – 11 - ene13α - y1 - (2R, 3S) – 3 – tert – butoxycarbonyl 
– amino – 2 - hydroxyphenylpropionate] or Taxotere®, RP56976, is a semi-
synthetic compound. It is modified from a non-toxic precursor, 10-deacetyl 
baccatin III, which is extracted from needles of the European yew tree (Taxus 
baccata L.). It is semi-synthetically prepared from 10-deacetyl baccatin III via a 
direct acylation at the C13 position and then esterified with a synthetic side chain 
(Shou et al., 1998; Clarke and Rivory, 1999). It has an anhydrous molecular 
weight of 807.9 or 861.9 in the trihydrate form. The chemical formula of 
docetaxel is C43H53NO14  (Clarke and Rivory, 1999). Docetaxel, a member of the 
taxane family, is a highly effective broad spectrum anticancer agent used in 
treatment of solid malignancies such as breast, ovarian, lung, head and neck 
cancers (Baker et al., 2006).  
 
Docetaxel acts as an anti-microtubule agent that stabilizes microtubulin assembly 
and inhibits depolymerisation, thereby disrupting the microtubule dynamic 
networks. This leads to a series of event including arrest in G2/M phase of the cell 
cycle and apoptosis. Docetaxel also inhibits angiogenesis, the process whereby 
tumors develop new capillary blood vessels (Herbst and Khuri, 2003). Figure 6 
summarized the effects of docetaxel in tumour cell. 
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Figure 6: An illustration of the effects of docetaxel on tumour cell. Docetaxel 
can be metabolised by CYP3A4 into inactive metabolites or export by P-
glycoprotein (p-gp) as it is a substrate of this transporter. Docetaxel also acts 
as an anti-microtubule agent that stabilizes microtubulin assembly and 
inhibits depolymerisation. This could leads to a series of event including 
arrest in G2/M phase of the cell cycle and apoptosis. 
Docetaxel 
Docetaxel 
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1.5.1 Docetaxel Metabolism and Elimination Pathway 
 
Docetaxel is metabolized mainly by hepatic CYPs and eliminated through the 
bile. The CYP3A class of enzymes dominates at this tissue site, therefore, it is 
necessary to address the two important members that played a key role docetaxel 
metabolism; CYP3A4 and CYP3A5 (Shou et al., 1998; Baker et al., 2006). Of 
these two enzymes, CYP3A4 is considered the main enzyme in docetaxel 
metabolism (Marre et al., 1996; Hirth et al., 2000). Unlike CYP3A4, CYP3A5 is 
polymorphically expressed in some individuals, varying greatly by race and 
ethnic group. Even though, individuals with polymorphically expressed CYP3A5 
isoform is capable of contributing approximately up to 50% of total hepatic CYPs 
or comparable level to CYP3A4, the latter is still the dominant contributor in 
docetaxel metabolism. It is believed that low expression of CYP3A4 in some 
adults is compensated by increased CYP3A5 polymorphic expression in these 
individuals. This suggests that individual difference in CYP3As expression may 
give rise to variability in docetaxel metabolism among individuals (Burk and 
Wojnowski, 2004; Vaclavikova et al., 2004).  
 
Docetaxel is metabolised by CYP3A4 to inactive metabolites (Figure 7). High 
CYP3A4 activity would, therefore, result in poor therapeutic outcome of the drug, 
while low CYP3A4 activity may cause toxicity in patients (Hirth et al., 2000; Goh 
et al., 2002; Rodriguez-Antona and Ingelman-Sundberg., 2006).  
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Besides individual variability in CYP3As expression, individual variability in 
nuclear receptor genes (PXR, CAR and HNF4α) that regulate CYP3As 
transcription is also a factor to take note of in docetaxel metabolism. Any 
sequence variation in these receptors would first affect the interaction between the 
receptors and ligand or CYP3As, followed by changes in the transcription 
activity. This cascade of reactions, in turn, may alter docetaxel metabolism by 
these CYP3As. A combination of factors such as genetic variation of CYP3A4 
regulatory genes (PXR, CAR and HNF4α) and CYP3A4 genotypes may influence 
the outcome of chemotherapy treatment in cancer patients. 
 
Docetaxel metabolism involves the initial hydroxylation of the methyl of the tert-
butyl ester group on the side chain that generates a primary alcohol metabolite; 
evident of CYPs metabolism. A subsequent oxidation of a putative aldehyde 
yields two diastereomeric hydroxyl-oxazolidinones after cyclization (Figure 7) 
(Shou et al., 1998; Baker et al., 2006). These non-cytotoxic inactive derivatives 
are then disposed off in faeces and urine. Cellular efflux of the metabolites is 
facilitated by intestinal efflux transporter P-glycoprotein (P-gp) (Baker et al., 
2006). It was also documented that docetaxel is also a substrate for P-gp but 
rather than being transport-dependent, CYP3A metabolism is the prominent 
elimination route for docetaxel. This was supported by observations whereby 
mice lacking the ABCB1 gene (also known as MDR1) that encodes P-gp have 
similar drug clearance as wild type mice (Baker et al., 2006). However, MDR1 
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Figure 7: Proposed metabolic pathways of docetaxel by CYP3A enzymes. Adapted 
from Shou et al., 1998, with permission from Lippincott & Williams Wilkins.  
Docetaxel (DOC) 
Hydroxy - DOC 
Aldehyde - DOC 
R- and S- Hydroxyoxazolidinones 
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2. OBJECTIVES AND OVERVIEW OF THE STUDY 
 
Drug metabolism and disposition is an important physiological process. With the 
daily exposure to exogenous chemicals or ‘xenobiotic’, such as food additives, 
pesticides, insecticides and pollutants either indigested in the diet or absorbed 
through the skin or lungs, the detoxification and elimination system forms a 
crucial surveillance role in the human body.  
 
Human CYP3A4 is a major CYP enzyme that is present abundantly in human 
liver and it influences the inter-individual variability of drug response and drug-
drug interaction in the human system. As mentioned in the previous chapter, 
nuclear receptors and transcription factors may be the important determinants of 
CYP3A4 transcriptional activation and regulation (Figure 8). 
 
In recent years, it has been acknowledged that genetic polymorphisms contribute 
to great alteration in terms of drug disposition or responsiveness. A large number 
of single nucleotide polymorphisms (SNPs) in the three genes (PXR, CAR and 
HNF4α) have been identified and reported in many populations such as African 
Americans, European and Asian like the Japanese. However, this has not been 
done in the local population. Therefore, it would be of great interest to determine 
the SNPs in PXR, CAR and HNF4α genes in the local population and to establish 
the importance (if any) of the identified SNPs as potential determinant of altered 
drug disposition profiles. 
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Singapore is a multiethnic country comprising of three major ethnic groups – 
Chinese, Malay and Indian. This study was carried out firstly to determine the 
polymorphisms in the coding regions of PXR, CAR and HNF4α genes in the three 
ethnic groups in normal control populations. After the screening for SNPs in the 
nuclear receptor genes of the ethnic groups, this study was taken further to screen 
for the SNPs in breast cancer patients treated with docetaxel. In vitro studies have 
demonstrated that CYP3A4 is the main enzyme involved in docetaxel metabolism 
(Marre F et al., 1996; Hirth et al., 2000). As mentioned earlier, CYP3A4 is 
transcriptional regulated by PXR, CAR and HNF4α (Figure 8), therefore, any 
SNPs in these receptor genes could possibly contribute to variability in docetaxel 
response and clearance in the cancer patients. The purpose of the second part of 
this study was thus to explore the role of PXR, CAR and HNF4α polymorphisms 
in the variability of docetaxel pharmacokinetics in the local population. An 
illustration of the study approach is shown in Figure 9. 
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Figure 8: A summary of the functions of PXR, CAR and HNF4α in drug detoxification 
and elimination. The nuclear receptors are activated by endogenous or exogenous drugs 
and bind to the consensus sequences on the CLEM4 or XREM regions of the CYP3A4 
gene. Together with the other phase I and II enzymes, the activated CYP3A4 will then 
“detoxify” the drugs. The toxicants and the metabolites are then eliminated by phase III 
transporters. 
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Figure 9:  Flow chart showing the study approach to identify PXR, CAR and HNF4α SNPs in 
healthy subjects and breast cancer patients. Screening of SNPs by BigDye V3.1 sequencing was 
first conducted in normal healthy subjects. Any identified SNPs by BigDye technique was 
confirmed by pyrosequencing. In the second part of the study, screening of SNPs was done for 
the breast cancer population in the same manner. Statistical analysis and data correlation (drug 
clearance) for the different genotype groups for the identified variants were conducted for the 
breast cancer population only.  
Extraction of patient genomic DNA 
                           PCR 
Amplification of individual exons from 
PXR, CAR and HNF4α genes 
BigDye V3.1 Sequencing 
Alignment of Sequences 
Pyrosequencing for identified SNPs in 
PXR, CAR and HNF4α genes.
Normal healthy subjects Breast cancer patients 
Statistical analysis 
A B 
Breast cancer population only 
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3. MATERIALS AND METHOD 
3.1 Materials 
The reagents needed for this study and the suppliers are listed in Table 3.   
 
Table 3: List of reagents needed for this study and the suppliers. 
Reagent Company 
Adriamycin Aventis Pharma BV, Hoevelaken, Netherlands 
Agarose BioRad 
BigDye Terminator V3.1 Applied Biosystems Inc 
Deoxyribonucleotide triphosphate 
(dNTP) 
New England Biolabs, Inc 
Docetaxel Aventis Pharma BV,  Hoevelaken, Netherlands 
DyNazyme DNA polymerase Finnzymes, Finland 
Ethidium bromide BioRad 
Exonuclease I GE Healthcare, US 
Gentra DNA Purification Kit Gentra Systems, Inc, Minneapolis, Minn 
Hi-Di Formamide Applied Biosystems Inc 
Magnetic beads Amersham Pharmacia Biotech, Uppsala, Sweden
PCR primers Proligo Singapore Pte Ltd 
Pyro sequencing primers Proligo Singapore Pte Ltd 
Shrimp Alkaline Phosphatase GE Healthcare, US 
TAE Buffer National University Medical Institute (NUMI) 
100bp DNA Ladder BioRad 
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3.2 Methods 
 
3.2.1 Study Population 
In this study, two groups of subjects were recruited. In the first group, a total of 
287 healthy subjects were screened for SNPs in the PXR, CAR and HNF4α genes. 
The healthy population consisted of 103 Chineses, 111 Malays and 73 Indians. In 
the second group, the study population comprised of 101 female patients with 
histologically or cytologically proven locally advanced or metastatic breast cancer 
who were receiving primary systemic chemotherapy. The breast cancer 
population consisted of 66 Chineses, 26 Malays, 7 Indians and 2 others. Subjects 
were randomized to receive one of two alternating sequences of adriamycin (A) 
and docetaxel (T), starting either with adriamycin 75mg/m2 as a slow bolus or 
docetaxel 75mg/m2 infused over one hour, every 3 weeks for 6 cycles 
(T→A→T→A→T→A or A→T→A→T→A→T). Plasma samples were obtained 
from each subject when they received their first cycle of docetaxel or adriamycin 
(Taxotere; Aventis Pharma BV, Hoevelaken, The Netherlands) for measurement 
of drug concentrations at the following time points. Time points for docetaxel: 
pre-dose, 1 hour, 2 hours, 4 hours, 7 hours, 10 hours, and 24 hours; and for 
adriamycin: pre-dose, 1 hour, 2 hours, 6 hours, 8 hours, 12 hours and 24 hours, 
following drug administration. Docetaxel concentrations were measured using an 
isocratic liquid chromatography/tandem mass spectrometry (LC/MS/MS) method 
as described previously (Guitton et al., 2005). Non-compartmental analysis for 
docetaxel was performed using Kinetica 4.4 (InnaPhase Corp., Philadelphia, PA), 
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and area under the concentration-time curve (AUC) was estimated using the log-
linear trapezoidal option from time 0 to infinity. The study protocol was approved 
by the Institutional Ethics Committee (DSRB, National University Hospital) and 
written informed consent was obtained from all patients according to institutional 
and governmental guidelines. 
     38
3.2.2 Genotyping 
 
 DNA extraction and amplification 
10ml of whole blood was collected from each subject, and genomic DNA was 
extracted from peripheral mononuclear cells using the Gentra DNA Purification 
Kit. The extraction was carried out according to the manufacturer’s protocol. 
Each exon from the PXR, the CAR or the HNF4α gene was amplified by 
polymerase chain reaction (PCR). The PCR reaction contained 100ng of genomic 
DNA, 0.5U of DyNAzyme DNA polymerase, 0.2 mM dNTP and 0.4 μM each of 
forward and reverse primers. The sequences of the PXR, CAR and HNF4α PCR 
primers are listed in Table 4, Table 5 and Table 6 respectively.  
 
PCR was performed using the Eppendorf Mastercycler (Eppendorf, USA), with 
an initial denaturing step at 920C to 950C for 2 minutes, followed by 30 to 35 
cycles of denaturing at 92 to 950C for 90 seconds, annealing at 55.50C to 670C for 
30 seconds, and extension at 720C for 1 minute. A final 10 minutes extension step 
at 720C was then carried out. 8μl of the PCR product was resolved by 1% 
ethidium bromide stained agarose gel electrophoresis. The size of the product was 
determined by comparing it against the 100bp DNA marker. The remaining PCR 
products were stored at -200C till required.  
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DNA Sequencing 
1μl of amplified PCR products were treated with 2.5U of Exonuclease (Exo) I and 
0.5U of Shrimp Alkaline Phosphatase (SAP) for 30 minutes at 370C to remove 
unincorporated nucleotides and primers. The reaction was stopped by heating at 
800C for 15 minutes. Treated PCR products were then sequenced using BigDye® 
Terminator v3.1 Cycle Sequencing Kit.  
 
The 20μl sequencing reaction mixture consisted of 4μl of Exo-SAP treated DNA 
template, 1 μl of BigDye, 3.5μl of the sequencing buffer, 1μl (10μM appropriate 
primer (forward or reverse primer) and 10.5 μl of water. The reaction was allowed 
to proceed in the Eppendorf Mastercycler (Eppendorf, USA) for 25 cycles. Each 
cycle consists of a denaturation step at 960C for 30 seconds, annealing at 500C for 
5 seconds, and extension at 600C for 4 minute. 3μl of 3M sodium acetate and 50μl 
of absolute ethanol were used to precipitate the extended DNA for an hour at -
200C. The sample was centrifuged at 12,000 rpm for 30 minutes. The pellet was 
then rinsed with 50μl of 70% ethanol and centrifuged for 10 minutes at 12,000 
rpm. The air dried pellet was dissolved in 13μl of Hi-Di Formamide and run on 
the ABI 3100 automated Sequence Analyzer (Applied Biosystems Inc), with the 
forward PCR primer and the reverse PCR primer. Any variants identified were 
confirmed by sequencing both the sense and the anti-sense strands as well as by 
pyrosequencing. Pyrosequencing was done to reassure that the variants identified 
were true and to re-confirm the alleles (homozygous or heterozygous) by 
comparing it against the classical Big Dye electropherogram.
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Pyrosequencing 
The pyrosequencing PCR reactions were performed using the Eppendorf 
Mastercycler (Eppendorf, US) in a total reaction volume of 30μl with 0.5U of 
DyNAzyme DNA polymerase, 0.2 mM dNTP and 0.4 μM each of forward and 
reverse primers listed in Table 7. For primers that required biotin labelling (PXR 
exon 1 reverse primer, CAR exon 5 forward primer and HNF4α Exon 4 forward 
primer), a ratio of 1:9 part (10μM) primer to universal primer stocks were made 
prior to use. PCR was carried out with an initial denaturing step at 950C for 4 
minutes, followed by 39 cycles of denaturing at 950C for 30 seconds, annealing at 
600C for 30 seconds, and extension at 720C for 30 seconds, followed by a final 1 
minute extension step at 720C. 
PCR products were incubated with 3µl of streptavidin magnetic beads and 1x 
binding buffer (10mM Tris–HCl, 2M NaCl, 1mM EDTA, 0.1% Tween 20) for 10 
minutes at 37oC. This is followed by denaturing the product mix for 5 seconds in 
0.2M NaOH solution. Washing was then carried out with annealing buffer (20mM 
Tris–acetate, 2mM magnesium acetate) for 10 seconds. The single-stranded 
products were then transferred to the annealing buffer containing 15pmol of the 
sequencing primer (see Table 7) and incubated for 2 minutes at 80oC in a Hybaid 
Maxi 14 hybridization oven (Thermo Electron, USA). Pyrosequencing was then 
performed on a PSQ96MA pyrosequencer (Biotage AB, Uppsala, Sweden). 
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Figure 10: The principle of pyrosequencing. Pyrosequencing is sequencing by synthesis 
and used for accurate and quantitative analysis of DNA sequences. [a] The first step in  
Pyrosequencing involves the hybridisation of sequencing primer to a single stranded PCR 
amplified DNA template in which the reaction is incubated with DNA polymerase, ATP 
sulfurylase, luciferase and apyrase. The reaction mix is incubated with the substrates, 
adenosine 5’ phosphosulfate (APS) and luciferin. [b] The first of the four 
deoxynucleotide triphosphates (dNTP) is added to the reaction. DNA polymerase 
catalyses the incorporation of the dNTP into the DNA strands. Each incorporation of 
dNTP results in the release of pyrophosphate (PPi) in a quantity equimolar to the amount 
of incorporated nucleotide. ATP sulfurylase quantitatively converts PPi to ATP in the 
presence of APS. This ATP drives the luciferase-mediated conversion of luciferin to 
oxyluciferin that generates visible light in amounts that are proportional to the amount of 
ATP. This light is then detected by a charge coupled device (CCD) camera and recorded 





ATP    Light 
Light 
Time





Primer Sequence  5’ to 3’ end 
 


































































Table 7: Forward and reverse primers for pyrosequencing. Primers with asterisk (*) 
mean they are biotinylated primers. All except HNF4α exon 1C were not pre-tagged 
with biotin during primer synthesis phase by Proligo Singapore Pte Ltd. HNF4α exon 
1C and universal primer were tagged with biotin at primer synthesis phase. Universal 
primer is required to be added together with the non-tagged biotin primer prior to use.  
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3.2.3 Alignment of Sequences.  
 
The nucleotide sequences of PXR, HNF4α and CAR genes were retrieved from 
GenBank. The PXR gene (GenBank accession number: AF364606), located on 
chromosome 3q12-q13.3, consists of nine exons. Exon 2 to 9 contains the coding 
region and exon 1 contains the 5’ untranslated region (UTR). The CAR gene 
(GenBank accession number: Z30425), located on chromosome 1q23.1, consists 
of 9 exons. The coding region of CAR spans from exon 2 through exon 9. The 
HNF4α gene (GenBank accession number: U72959 to U72969), located on 
chromosome 20q12-q13.1, consist of 10 exons with 3 sub exon 1 (1A, 1B, 1C), 
all spanning the coding region (Ryffel, 2001). Sequence alignments were 
performed using the Multiple Sequence Alignment program by Florence Corpet 
(http://prodes.toulouse.inra.fr/multalin/multalin.html) (Corpet, 1988). 
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3.2.4 Statistical Analysis. 
 
Descriptive statistics were used to study the population distribution of docetaxel 
clearances. Analysis of genotypes with continuous pharmacokinetics parameters 
such as docetaxel clearances, body surface area normalized clearance (CL), 
maximum concentration (Cmax), area under the curve (AUC) and half life (t1/2) 
were performed using the student’s t-test or one-way ANOVA test as appropriate. 
All genetic variants were tested for departure from Hardy-Weinberg equilibrium 
for each ethnic group using Chi square test with one degree of freedom. All 
docetaxel kinetics data were provided by Dr Goh Boon Cher and Dr Lee Soo 
Chin, Department of Haematology-Oncology, National University Hospital, 
Singapore. Statistical analyses were performed using SPSS Version 11.5 (SPSS 
Inc, Chicago I11), with P ≤0.05 considered to be statistically significant. 
 
Derivation of area under curve (AUC) 
 
AUC (0 – infinity) = Dose / CL 
 
AUC is referred to as the area under the plasma (serum or blood) concentration 
versus time curve. It is most commonly derived by the trapezoidal method. For 
example, breaking up the areas in trapezoids (or segments), and making a 
summation of the areas of each trapezoid which can be calculated by multiplying 
the average concentration by the segment width. (http://www.boomer.org) 
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 Derivation of clearance (CL) 
 
  CL =  Dose / AUC 
  
Clearance is describes how quickly drugs are eliminated, metabolised or 
distributed throughout the body. Clearance can be calculated by measuring the 
amount of drug eliminated during some time interval and the drug concentration. 
The total amount of drug that can be eliminated is the total amount administrated, 
that is the dose. (http://www.boomer.org) 
 
Derivation of half-life (t1/2) 
  
 t1/2 = ln 2 / k    or  t1/2 = 0.693 / k 
 
The half-life is the time taken for the plasma concentration to fall to half its 
original value. k is the elimination rate constant describing removal of drug by all 
elimination processes. (http://www.boomer.org) 
 
The elimination rate constant can be calculated as follows: 
 
 Elimination rate constant (k) = 1 / time 
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4. RESULTS 
  
The liver is the main organ for xenobiotic metabolism and the major CYP enzyme 
that is expressed in the liver is CYP3A4. The expression of CYP3A4 can be 
regulated by various nuclear receptors and transcription factors. These include 
PXR, CAR and HNF4α. In this study, the aim is to examine the polymorphisms in 
the genes encoding these receptors. The populations used in this study include 
firstly, healthy subjects (comprising of Chinese, Malays and Indians) and 
secondly, a cohort of breast cancer patients. 
 
 
4.1 Screening of PXR, CAR and HNF4α Genes in Local Healthy Population 
 
4.1.1 Amplification of Exons and Sequencing 
 
 In the first part of this study, screening was carried out on all the exons of the 
PXR, CAR and HNF4α genes in 287 healthy subjects comprising of 103 Chinese, 
111 Malays and 73 Indians. Amplification of the exons from genomic DNA was 
achieved by PCR and this was followed by sequencing (see Figure 11, 12 and 13). 
Sequencing was carried out for both the sense and anti-sense strand. Sequences 
from subjects that were homozygous and heterozygous were first identified via 
the electropherogram obtained through Big Dye sequencing (aligned against the 
wild type sequence) and then confirmed by pyrosequencing. Amplification of the 
individual SNP exon for pyrosequencing reaction (see Figure 14) was achieved by 
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PCR using the respective pyrosequencing primers (see Table 7). An example of 
the electropherogram showing the nucleotide changes for the three genes is shown 






Figure 11: PCR amplification of all nine PXR exons from patient genomic DNA. 
The PCR product size are (a) exon 1, 635bp; (b) exon 2, 541bp; (c) exon 3, 
518bp; (d) exon 4, 721bp; (e) exon 5, 649bp; (f) exon 6, 525bp; (g) exon 7, 







Figure 12: PCR amplification of all eight CAR exons from patient genomic DNA. 
The coding region in the CAR gene begins at exon 2 and ends at exon 9. The PCR 
product size are (a) exon 2, 558bp; (b) exon 3, 512bp; (c) exon 4, 582bp; (d) exon 
5, 545bp; (e) exon 6, 803bp; (f) exon 7, 387bp; (g) exon 8, 525bp; and (h) exon 9, 
453bp.  
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                                  CAR Exon 











Figure 13: PCR amplification of all twelve HNF4α exons from patient genomic 
DNA. The PCR product size are (a) exon 1A, 537bp; (b) exon 1B, 399bp; (c) 
exon 1C, 537bp; (d) exon 2, 444bp; (e) exon 3, 389bp; (f) exon 4, 474bp; (g) exon 
5, 612bp; (h) exon 6, 624bp; (i) exon 7, 676bp; (j) exon 8, 649bp; (k) exon 9, 





           
 
Figure 14: PCR amplification of PXR exon 1, CAR exon 5, HNF4α exon 1C and 
HNF4α exon 4 from patient genomic DNA using pyrosequencing primers. The 
PCR products were used for pyrosequencing reaction. The PCR products are (a) 
PXR exon 1, 225bp; (b) CAR exon 5, 135bp; (c) HNF4α exon 1C, 229bp; and (d) 
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               HNF4α exon 1C A>G (Met49Val)                HNF4α exon 4 C>T (Thr130Ilel) 
 
Figure 15: Electropherograms of PXR, CAR and HNF4α SNPs. Arrows indicate 
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4.1.2 Variants in the PXR, CAR and HNF4α Genes 
 
The variants that were observed in the local population include the A>C at -24381 
for the PXR gene, the C>T at the codon 180 for the CAR gene, the A>G and C>T 
at the codon 49 and codon 130 for the HNF4α gene respectively (Table 8). These 
had all been previously reported in other studies (Moller et al., 1997; Price et al., 
2000; Rissanen et al., 2000; Sakurai et al., 2000; Zhang et al., 2001; Ikeda et al., 
2003; Pruhova et al., 2003; Lamba et al., 2005; Ek et al., 2005; Bosch et al., 
2006). The CAR variant is a silent coding region variant (Pro180Pro). This proline 
residue is located in the ligand-binding domain of the receptor (Lamba et al., 
2005). The PXR variant is a 5’UTR variant. Both the HNF4α variants are non-
synonymous coding region variants; Met49Val and Thr130Ile in exon 1C and 
exon 4 respectively. The HNF4α Met49Val and Thr130Ile variants are located in 
the N-terminal functional domain and the DNA binding domain of the receptor, 
respectively (Hadzopoulou-Cladaras et al., 1997; Jiang and Sladek, 1997; Jakob 
et al., 2005). 
 
The genotypic distribution and allele frequencies of PXR, CAR and HNF4α 
polymorphic variants in different ethnic groups shown in Table 9. The allele 
frequencies for the three genes were similar for the Chinese and Malay ethnic 
groups. However, for the Indian subjects, the distribution was different with the 
exception of the frequencies for the HNF4α exon 4 variant, Thr130Ile. No 
homozygous was observed for HNF4α Thr130Ile in all the three ethnic groups. 
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Heterozygous for HNF4α Thr130Ile reported in this study was rare with 
frequency of  ≤ 0.05. 
 
A comparison of what was obtained for our subjects was also carried out with 
those previously described for other population (Moller et al., 1997; Price et al., 
2000; Rissanen et al., 2000; Sakurai et al., 2000; Zhang et al., 2001; Ikeda et al., 
2003; Pruhova et al., 2003; Lamba et al., 2005; Ek et al., 2005; Bosch et al., 
2006). The results of this comparison are shown in Table 10, Table 11, Table 12 
and Table 13. In general, what we had observed in our three ethnic groups were 
different from these population with a few exceptions. The allele frequencies for 
the Indian and Dutch population for the PXR variant were similar while the 
Caucasian, the Chinese and the Malay population showed that the wild-type 
occurs in about 60% of these populations. The reported value for the African 
American subjects was very much lower (Table 10). However, this value may not 
be accurate as the sample size was very small (n=20). It is of interest to note that 
for the HNF4α exon 4 variant, the wild type predominates in more than 95% of 
all populations (Table 13). In addition, no homozygous was detected for this 
variant. This may be due to the fact that this amino acid residue is located in the 
DNA binding domain and it may be critical for the function of this nuclear factor.  
 
The allele frequencies for the Chinese and Malay population for the CAR exon 5 
variant were similar, reporting a low wild type frequency value of 0.18 compared 
to the Japanese population with almost half of the population having SNPs in this 
gene (Table 11). Our study reported similar HNF4α exon 1C allele frequencies 
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between the Chinese and Malay population (wild-type frequency = 0.28) and 
much lower for the Indian population (wild-type frequency = 0.12). The allele 
frequencies for all the three ethnic groups in this study were very different from 
those in reported population (Czech and Japanese). It is noted that the minor allele 
for the HNF4α exon 1C in all three ethnic groups in the local populations is 
actually the major allele in the Czech and Japanese populations (see Table 12). 
These differences may be attributed to genetic selection, dietary or environmental 
influences or to drug interactions. HNF4α exon 1C wild type predominates in 
more than 70% in both the Czech and Japanese population (see Table 12). 
 
The other known reported exonic or intronic SNPs beside the ones studied in this 
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Table 8: Polymorphisms identified in the PXR, CAR and HNF4α gene in the healthy 
control population (n = 287). In the screening of the breast cancer population (n = 
101), the same set of four SNPs were identified in the three genes. No additional 
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                                      Allele Frequency  
 Location and  













(n = 73) 
 
PXR gene 
- 24381 A > C 
 
AA = 0.66 
AC = 0.31 
CC = 0.03 
 
AA = 0.61 
AC = 0.36 
CC = 0.03 
 
AA = 0.46 
AC = 0.44 





CC = 0.18 
CT = 0.46 
TT = 0.36 
 
CC = 0.18 
CT = 0.54 
TT = 0.28 
 
CC = 0.23 
CT = 0.60 






AA = 0.28 
AG = 0.42 
GG = 0.30 
 
AA = 0.28 
AG = 0.44 
GG = 0.28 
 
AA = 0.12 
AG = 0.44 





CC =  0.95 
CT = 0.05 
 
CC = 0.98 
CT = 0.02 
 
CC = 0.95 
CT = 0.05 
 
Table 9: Genotypic distribution and allele frequencies of PXR, CAR and HNF4α 
variants in healthy control. PXR gene (- 24381 A > C): AA, AC and CC are wild 
type, heterozygous and homozygous respectively. CAR gene (Pro180Pro): CC, 
CT and TT are wild type, heterozygous and homozygous respectively. HNF4α 
gene (Met49Val): AA, AG and GG are wild type, heterozygous and homozygous 
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Table 10: Comparison of SNP frequencies of PXR exon 1 variant. Study population 
include Singaporean (comprising of Chinese, Malays and Indians), African American, 





Table 11: Comparison of SNP frequencies of CAR exon 5 variant. Study population 








Population Number of Subjects Allele Frequency Reference 
Singapore Chinese 103 0.66 / 0.34 ----- 
Singapore Malay 111 0.61 / 0.39 ----- 
Singapore Indian 73 0.46 / 0.54 ----- 
African American 20 0.27 / 0.73 Zhang et al., 2001 
Caucasian 150 0.59 / 0.41 Zhang et al., 2001 
Dutch 100 0.46 / 0.54 Bosch et al., 2006 
Population Number of Subjects Allele Frequency Reference 
Singapore Chinese 103 0.18 / 0.82 ----- 
Singapore Malay 111 0.18 / 0.82 ----- 
Singapore Indian 73 0.23 / 0.77 ----- 
Japanese 253 0.48 / 0.52 Ikeda et al., 2003 
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Table 12: Comparison of SNP frequencies of HNF4α exon 1C variant. Study population 




Table 13: Comparison of SNP frequencies of HNF4α exon 4 variant. Study population 
include Singaporean (comprising of Chinese, Malays and Indians), Caucasian, Chinese, 
Czech, Danish, Japanese and Swedish. 
Population Number of Subjects Allele Frequency Reference 
Singapore Chinese 103 0.28 / 0.72 ----- 
Singapore Malay 111 0.28 / 0.72 ----- 
Singapore Indian 73 0.12 / 0.88 ----- 
Caucasian 100 0.08/ 0.92 Price et al., 2000 
Czech 61 0.73 / 0.27 Pruhova et al., 2003 
Japanese 100 0.95 / 0.05 Sakurai et al., 2000 
Population Number of Subjects Allele Frequency Reference 
Singapore Chinese 103 0.95 / 0.05 ----- 
Singapore Malay 111 0.98 / 0.02 ----- 
Singapore Indian 73 0.95 /0.05 ----- 
Caucasian 100 0.99 / 0.01 Price et al., 2000 
Chinese 52 0.96 / 0.04 Rissanen et al., 2000
Czech 61 0.98 / 0.02 Pruhova et al., 2003 
Danish 239 0.98 / 0.02 Moller et al., 1997 
Danish 369 0.95 / 0.05 Moller et al., 1997 
Danish 4726 0.97 / 0.03 Ek et al., 2005 
Japanese 100 1.0 / 0 Sakurai et al., 2000 
Swedish 666 0.95 / 0.05 Moller et al., 1997 
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4.2 Screening of PXR, CAR and HNF4α Genes in the Breast Cancer Population 
 
PXR, CAR and HNF4α are known to be master transcriptional regulators of 
CYP3A4 gene, which played an eminent role in drug metabolism. We postulated 
that any SNPs in these receptor genes could affect CYP3A4 gene transcription 
which may lead to possible variation in drug clearance in the patients.  
 
In the second part of this study, 111 female breast cancer patients were recruited 
and the exons of the PXR, CAR and HNF4α genes were analysed. This cohort 
included 66 Chinese, 26 Malays, 7 Indians and 2 of other ethnic origins. The 
mean age of the study population was 45.6 ± 12 years. The variants that were 
observed in the three genes studied were identical to those observed for the 
healthy local population (see Table 8 and Table 14). The genotypic distribution 
and frequency of PXR, CAR and HNF4α polymorphic variants for all 101 breast 
cancer patients are summarised in Table 14. Allele frequency of the four variants 
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Location and Designation Allele Frequency 
 
PXR gene 
-24381 A > C 
AA = 0.60 
AC = 0.31 
CC = 0.09 
CAR gene 
Pro180Pro 
CC = 0.26 
CT = 0.41 
TT = 0.33 
HNF4α gene 
Met49Val 
AA = 0.24 
AG = 0.41 
GG = 0.35 
HNF4α gene 
Thr130Ile 
CC = 0.98 
CT = 0.02 
                TT = 0   
 
Table 14: Genotypic distribution and allele frequencies of PXR, CAR and HNF4α 
variants in breast cancer patients (n = 101). PXR gene (- 24381 A > C): AA, AC 
and CC are wild type, heterozygous and homozygous respectively. CAR gene 
(Pro180Pro): CC, CT and TT are wild type, heterozygous and homozygous 
respectively. HNF4α gene (Met49Val): AA, AG and GG are wild type, 
heterozygous and homozygous respectively. HNF4α gene (Thr130Ile): CC, CT 
and TT are wild type, homozygous and heterozygous respectively. 























Table 15: Genotypic distribution and allele frequencies of PXR, CAR and HNF4α  
for the different ethnic groups in the breast cancer population (n = 101). In the 
cohort of 101 patients, there are 66 Chinese, 26 Malays, 7 Indians and 2 of other 
ethnic origins. PXR gene (- 24381 A > C): AA, AC and CC are wild type, 
heterozygous and homozygous respectively. CAR gene (Pro180Pro): CC, CT and 
TT are wild type, heterozygous and homozygous respectively. HNF4α gene 
(Met49Val): AA, AG and GG are wild type, heterozygous and homozygous 
respectively. HNF4α gene (Thr130Ile): CC, CT and TT are wild type, 
homozygous and heterozygous respectively. 
Allele Frequency  
Variant  
Chinese 
(n = 66) 
 
Malay 
(n = 26) 
 
Indian 




(n = 2) 
 
PXR gene 
- 24381 A > C 
 
AA = 0.56 
AC = 0.36 
CC = 0.08 
 
AA = 0.77 
AC = 0.19 
CC = 0.04 
 
AA = 0.29 
AC = 0.29 
CC = 0.42 
 
 AA = 1.00 
 AC = 0 





CC = 0.24 
CT = 0.48 
TT = 0.28 
 
CC = 0.30 
CT = 0.35 
TT = 0.35 
 
CC = 0.29 
CT = 0.14 
TT = 0.57 
 
  CC = 0 
  CT = 0 






AA = 0.23 
AG = 0.38 
GG = 0.39 
 
AA = 0.27 
AG = 0.46 
GG = 0.27 
 
  AA = 0 
AG = 0.71 
GG = 0.29 
 
 AA = 1.00 
 AG = 0 





CC =  0.97 
  CT = 0.03 
  TT = 0 
 
CC = 1.00 
  CT = 0 
  TT = 0 
 
CC = 1.00 
  CT = 0 
  TT = 0 
 
 CC = 1.00 
  CT = 0 
  TT = 0 
     63
4.3 Comparing the Allele Frequencies between Local Healthy and Breast Cancer 
Population 
 
It was not appropriate to compare the allele frequencies between different ethnic 
groups of both healthy and breast cancer population as the sample size differs 
greatly. The sample size for Chinese (n = 66), Malay (n = 26) and Indian (n = 7) 
in the breast cancer cohort were too small to conduct a fair comparison against the 
healthy patient cohort.  Therefore, we compared the allele frequency observed in 
the three ethnic groups for the local healthy population against the breast cancer 
population as a whole. The allele frequencies for the Chinese, Malay and breast 
cancer patients for the PXR variant were similar, showing that the wild-type 
occurs in about 60%. CAR exon 5 variant (Pro180Pro) and HNF4α exon 1C 
variant (Met49Val), too, showed similar allele frequencies distribution for the 
Chinese, Malay and breast cancer population. The only variant that displayed 
similar allele frequency across all the ethnic groups and the breast cancer 
population is HNF4α exon 4 variant (Thr130Ile). As discussed in previous 
section, HNF4α exon 4 wild-type predominates in more than 95% of all 
populations. This may be because this amino acid residue plays a crucial 
functional role for this nuclear factor. 
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4.4 Pharmacokinetics Correlations  
 
Following the sequencing and genotyping for the breast cancer population, 
statistical analysis test was carried out to determine if there were any correlations 
between drug clearance and individual genotype groups. Analysis was also done 
to determine whether the SNPs in the PXR, CAR and HNF4α genes affected the 
metabolism of docetaxel in these breast cancer patients. The correlation was done 
for only 97 subjects as 4 subjects dropped out in the midst of study. No significant 
correlations were observed between the genotypes and the docetaxel clearance; 
body surface area (BSA) normalized docetaxel clearance, Cmax, AUC or half-life 
(t1/2).  
 
The docetaxel clearances by PXR, CAR and HNF4α genotype are shown in Figure 
16. BSA normalised docetaxel clearance, Cmax, AUC and half life by PXR, CAR 
and HNF4α genotype are also shown in Figure 17, Figure 18, Figure 19 and 
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Figure 16: [A] Docetaxel clearance (L/h/m2) against PXR exon 1 genotype. AA, AC, and CC 
represent wild type, heterozygous and homozygous respectively. [B] Docetaxel clearance 
(L/h/m2) against CAR exon 5 genotype. CC, CT, and TT represent wild type, heterozygous 
and homozygous respectively. [C] Docetaxel clearance (L/h/m2) against HNF4α exon 1C 
genotype. AA, AG, and GG represent wild type, heterozygous and homozygous respectively. 
[D] Docetaxel clearance (L/h/m2) against HNF4α exon 4 genotype. CC and CT represent 
wild type and heterozygous respectively. The bar indicates the mean docetaxel clearance 
value. Statistical analysis result in p-values > 0.05. 
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Figure 17: [A] BSA normalised docetaxel clearance (L/h/m2) against PXR exon 1 genotype. AA, 
AC, and CC represent wild type, heterozygous and homozygous respectively. [B] BSA 
normalised docetaxel clearance (L/h/m2) against CAR exon 5 genotype. CC, CT, and TT represent 
wild type, heterozygous and homozygous respectively. [C] BSA normalised docetaxel clearance 
(L/h/m2) against HNF4α exon 1C genotype. AA, AG, and GG represent wild type, heterozygous 
and homozygous respectively. [D] BSA normalised docetaxel clearance (L/h/m2) against HNF4α 
exon 4 genotype. CC and CT represent wild type and heterozygous respectively. The bar 
indicates the mean BSA normalised docetaxel clearance value. Statistical analysis result in p-
values > 0.05. 
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Figure 18: [A] Maximum concentration of docetaxel, Cmax, (mg/L) against PXR Exon 1 
genotype. AA, AC, and CC represent wild type, heterozygous and homozygous respectively. 
[B] Maximum concentration of docetaxel, Cmax, (mg/L) against CAR Exon 5 genotype. CC, 
CT, and TT represent wild type, heterozygous and homozygous respectively. [C] Maximum 
concentration of docetaxel, Cmax, (mg/L) against HNF4α exon 1C genotype. AA, AG, and 
GG represent wild type, heterozygous and homozygous respectively. [D] Maximum 
concentration of docetaxel, Cmax, (mg/L) against HNF4α exon 4 genotype. CC and CT 
represent wild type and heterozygous respectively. The bar indicates the mean Cmax value. 
Statistical analysis result in p-values > 0.05. 
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Figure 19: [A] Area under curve, AUC, (mg/L*h) against PXR Exon 1 genotype. AA, AC, 
and CC represent wild type, heterozygous and homozygous respectively. [B] Area under 
curve, AUC, (mg/L*h) against CAR Exon 5 genotype. CC, CT, and TT represent wild type, 
heterozygous and homozygous respectively. [C] Area under curve, AUC, (mg/L*h) against 
HNF4α exon 1C genotype. AA, AG, and GG represent wild type, heterozygous and 
homozygous respectively. [D] Area under curve, (mg/L*h), against HNF4α exon 4 genotype. 
CC and CT represent wild type and heterozygous respectively. The bar indicates the mean 
AUC value. Statistical analysis result in p-values > 0.05. 
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Figure 20: [A] Half life, t1/2, (hours) against PXR Exon 1 genotype. AA, AC, and CC represent 
wild type, heterozygous and homozygous respectively. [B] Half life, t1/2, (hours) against CAR 
Exon 5 genotype. CC, CT, and TT represent wild type, heterozygous and homozygous 
respectively. [C] Half life, t1/2, (hours) against HNF4α exon 1C genotype. AA, AG, and GG 
represent wild type, heterozygous and homozygous respectively. [D] Half life, t1/2, (hours) against 
HNF4α exon 4 genotype. CC and CT represent wild type and heterozygous respectively. The bar 
indicates the mean t1/2 value. Statistical analysis result in p-values > 0.05.  
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5. DISCUSSION 
 
In recent years, drug therapy has placed its focus exclusively on factors 
determining systemic drug disposition (distribution and clearance). The 
application of pharmacogenetic approaches to optimize drug dosage and treatment 
regimes is critically important as it provides therapeutic control in the 
pharmacotherapy in individual patients (Brouwer and Pollack, 2002). 
 
The nuclear hormone receptors PXR, CAR and HNF4α play important roles as 
xenobiotic-sensing receptors, transcription enhancers and regulators that serve to 
regulate the expression of drug metabolizing enzymes and drug transporters. 
SNPs, insertions, deletions and microsatellite polymorphism in these three nuclear 
receptors may contribute to clinically significant variations in drug metabolizing 
enzyme activities, which may in turn have major effects on drug clearance, 
efficacy, and toxicity.  
 
As discussed earlier, the main drug metabolising CYP isoform is CYP3A4. There 
is considerable inter-individual variation in CYP3A4 activity and expression. 
Approximately 90% of these CYP3A4 variations were thought to be caused by 
genetic factors (Ingelman-Sundberg, 2004). From previous studies, the CYP3A4 
variants identified are either rare among populations or occur with low allele 
frequencies (Dai et al., 2001; Hsieh et al., 2001; Lamba et al., 2002; Bosch et al., 
2006; Du et al., 2006). This makes it difficult to relate CYP3A4 genotype to the 
pharmacokinetics and pharmacodynamics of CYP3A4 substrates (Bosch et al., 
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2006). Thus, it is necessary to examine the genes that regulate CYP3A4 
transcription. Looking into the genetic variations of the regulatory genes such as 
PXR, CAR and HNF4α may help to explain any possible genetic basis for the 
inter-individual variability in the expression of CYP3A4 (Ingelman-Sundberg, 
2004; Bosch et al., 2006). 
 
 
5.1 Exonic Variants in PXR, CAR and HNF4α Genes 
 
We sequenced the human PXR, CAR and HNF4α genes and identified a total of 
four SNPs and determined their allelic frequencies in both the healthy control and 
breast cancer population. The four variants that were observed were: PXR 5’-UTR 
variant (-24381A>C), CAR (Pro180Pro), HNF4α (Met49Val) and HNF4α 
(Thr130Ile). 
 
For the PXR gene, the SNP that was observed was in the 5’UTR. Comparison of 
the three Singaporean ethnic groups with other populations (Table 10) showed 
that the allele frequencies for this variant were similar for the Chinese and Malay 
population. This is also similar to that reported in a study with Caucasian subject 
(Zhang et al., 2001). However, the local Indian population have a lower 
occurrence of the wild-type allele and shows similar occurrence as that of a Dutch 
study (Bosch et al., 2006). It is unclear what functional consequence this A>C 
change may have. It may be possible that this change which is not within the 
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open-reading frame of PXR may influence transcription initiation. Alternatively, it 
may also impact on translation of the PXR transcription by influencing ribosomal 
binding. 
 
The only CAR variant found in this study is a synonymous SNP in exon 5 
(Pro180Pro). This proline residue is located within the ligand-binding domain. In 
all the three local ethnic groups, more than 45% of the population are 
heterozygous and the allele frequency is more than 0.75. In contrast, the 
frequency reported in for a Japanese study was 0.52 (Ikeda et al., 2003). What 
functional consequence this variant has is currently unclear. It may be that there is 
no functional consequence since this is a synonymous SNP and most variations in 
CAR function are associated with splice variants rather than coding region 
polymorphisms (Okey et al., 2005) 
 
Two non-synonymous SNPs in exon 1C (Met49Val) and exon 4 (Thr130Ile) were 
detected for the HNF4α gene, In the Singaporean population, the allele frequency 
for Met49Val is very different from that of Czech and Japanese population (Table 
12). The variant predominates at a much higher frequency than that previously 
reported. The Met49Val variant is located in the N-terminal functional domain 
AF-1, also referred to as the A/B domain. The AF-1 plays a crucial role in 
HNF4α-mediated transcription regulation and recruitment of co-activators. It has 
been demonstrated that AF-1 is indispensable for HNF4α function. Absence of 
AF-1 led to decrease in both the transcriptional potential and interaction with co-
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activators (Green et al., 1998; Eeckhoute et al., 2001; Kistanova et al., 2001; 
Eeckhoute et al., 2003). However, to date, there has been no study carried out to 
examine the effect of mutating Met49 to Val. Thus, it is not possible to determine 
as yet if such a change has any functional consequence although in our breast 
cancer cohort, this variant is not associated with any of the examined parameters 
of docetaxel pharmacokinetics.  
 
The other non-synonymous SNP for the HNF4α gene was Thr130Ile. This variant 
has been shown to occur in very low frequencies in most populations examined 
(this study and that of in the Caucasian, Chinese, Czech, Danish, Japanese and 
Swedish studies). Thr130Ile variant is located in the D domain, which is involved 
in DNA binding. In vitro transactivation studies have been carried out for this 
missense polymorphism. When compared to the wild-type, a significant decrease 
in transactivation activity was observed for the Thr130Ile variant (Ek et al., 
2005). This together with the observation that no heterozygous was observed 
certainly indicates that Thr130Ile is critical to the function of HNF4α. 
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5.2  PXR, CAR and HNF4α Genotypes and Docetaxel Pharmacokinetics 
 
CYP3A4 is the main enzyme involved in the metabolism of docetaxel. The 
expression of CYP3A4 is transcriptionally regulated by various nuclear receptors 
including PXR, CAR and HNF4α. Hence, in this study, we also sequenced the 
exons of the human PXR, CAR and HNF4α genes of a cohort of breast cancer 
patients undergoing docetaxel treatment. Similar to that observed for our healthy 
population, four variants, namely PXR 5’ UTR variant (-24381 A>C), CAR 
(Pro180Pro), HNF4α (Met49Val) and HNF4α (Thr130Ile) were observed in the 
breast cancer patients. The allele frequencies observed in the breast cancer 
population were similar to that observed for the Chinese and Malays. 
 
Pharmacokinetics analysis was performed for the breast cancer population and no 
clear correlation was found between the different genotypes and docetaxel 
pharmacokinetics. What was noteworthy was the lack of significant correlation 
for the HNF4α (Met49Val). There was no difference in all pharmacokinetic 
parameters between patients who are wild-type, heterozygous or homozygous 
despite the fact that this SNP occurs in the AF-1 domain which is important for 
interaction and recruitment of co-activators. 
 
One possible explanation to why no clear correlation was found could be due 
unequally distribution or numbers of patients in each individual ethnic group. By 
combining the three ethnic groups data for pharmacokinetics analysis could have 
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skewed the result of genotypes correlation to docetaxel pharmacokinetics data. 
Table 15 illustrated that different ethnic groups have different allele frequencies 
and not at all similar across the board. As known, the three ethnic groups have 
different dietary preferences, different racial origin and possible different gene 
selection.  
 
To improve the accuracy of analysis, a larger sample size for each race should be 
recruited. In addition, a more robust index should be set for the measurement of 
plasma concentration or docetaxel pharmacokinetics, although all these would be 
logistically demanding. 
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6.  CONCLUSION 
 
In conclusion, our study identified four exonic variants in the PXR, CAR and 
HNF4α genes. All variants were observed in each of the three major ethnic 
groups examined but the frequencies were different between that of the Indians 
when compared to the Chinese and Malays. The allele frequencies observed for 
the local population was also generally different from that of other studies carried 
out with mainly Caucasian and Japanese subjects. 
 
Given the role of PXR, CAR and HNF4α in regulating the expression of CYP3A4, 
we had hypothesized that genetic polymorphisms of PXR, CAR and HNF4α 
would affect CYP3A4 expression and this would in turn alter docetaxel clearance 
and kinetics. However, we did not observe any correlation. Therefore, to 
completely rule out the lack of correlation, various addition factors need to be 
examined. A detail examination for polymorphisms in the PXR, CAR and HNF4α 
genes has to be carried out to include polymorphisms in the promoter regions of 
the genes as well as polymorphisms in the intron / splice sites. In addition, a 
larger cohort of patients with sufficient representation of the various ethnic groups 
needs to be recruited. 
 
Given the major role of CYP genes and its associated transcriptional regulators 
such as PXR, CAR and HNF4α in drug elimination, the variability of SNPs 
examined in both ethnically diverse healthy and breast cancer populations might 
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be helpful in providing a clearer interpretation of inter-individual variability in 
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